Hutchison China Meditech Limited Results of Annual General Meeting (4310M)
27 April 2018 - 10:52PM
UK Regulatory
TIDMHCM
RNS Number : 4310M
Hutchison China Meditech Limited
27 April 2018
Results of Annual General Meeting
London: Friday, April 27, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary
resolutions and special resolutions put to its Annual General
Meeting ("AGM") held on April 27, 2018 were duly passed. The poll
results of the resolutions were as follows:
Number of Votes (%)*
Resolutions For Against Withheld(#)
To consider and adopt the
audited financial statements
and the reports of the
directors and independent
auditor for the year ended
1 31 December 2017. 43,747,211 230 0
(99.99947%) (0.00053%)
To re-elect Mr Simon To
2 as a director. 43,207,556 353,263 186,622
(99.18903%) (0.81097%)
To re-elect Mr Christian
3 Hogg as a director. 43,742,340 4,901 200
(99.98880%) (0.01120%)
To re-elect Professor Tony
4 Mok as a director. 43,747,241 0 200
(100.00000%) (0.00000%)
To re-elect Ms Edith Shih
5 as a director. 43,742,310 4,931 200
(99.98873%) (0.01127%)
To re-appoint PricewaterhouseCoopers
as the auditor of the Company
and authorise the board
of directors to fix the
6 auditor's remuneration. 43,747,211 230 0
(99.99947%) (0.00053%)
To grant
a general
mandate to
the directors
of the Company
to issue
Ordinary Resolution additional
7 No. 7(A) : shares. 43,746,866 575 0
(99.99869%) (0.00131%)
To disapply
pre-emption
Special Resolution rights (general
No. 7(B) : power). 42,520,006 552,895 674,540
(98.71637%) (1.28363%)
To disapply
pre-emption
rights (in
connection
with an acquisition
Special Resolution or specified
No. 7(C) : capital investment). 41,723,007 1,349,894 674,540
(96.86602%) (3.13398%)
To grant
a general
mandate to
the directors
of the Company
to repurchase
Ordinary Resolution shares of
No. 7(D) : the Company. 43,746,636 805 0
(99.99816%) (0.00184%)
* Percentages rounded to 5 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
As at the date of the AGM, the number of issued shares of
Chi-Med was 66,484,620, which was the total number of shares
entitling the holders to attend and vote on the ordinary
resolutions and special resolutions proposed at the AGM.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSESFEWFASEIL
(END) Dow Jones Newswires
April 27, 2018 08:52 ET (12:52 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024